AbbVie reports strong Q2 2025 results with Solid Immunology and Neuroscience growth

ByInvestment Club

Overview

AbbVie delivered strong operational performance in the second quarter of 2025, supported by double-digit growth in Immunology and Neuroscience. Net revenues increased to $15.42bn, reflecting portfolio expansion and continued demand for key growth products.

CEO Richard Gonzalez emphasized that AbbVie’s diversified portfolio and advancing pipeline position the company for sustainable long-term growth despite ongoing Humira biosimilar erosion: “AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation. We’re entering the second half of the year with substantial momentum and are once again raising our full-year outlook”.

Q2 2025 vs. Q2 2024:

  • Net revenues reached $15.42bn (+6.6% YoY and +6.5% on an operational basis).
    • Global Immunology revenue was $7.63bn (+9.5% YoY). Skyrizi generated $4.42bn in revenue (+62% YoY), and Rinvoq generated $2.03bn (+42% YoY), while Humira declined to $1.18bn (-58% YoY).
    • Neuroscience revenue reached $2.68bn (+24% YoY). Growth was led by Vraylar at $900m (+16% YoY), Botox Therapeutic at $928m (+14% YoY), and strong demand for Ubrelvy and Qulipta, which increased 47% and 78% YoY, respectively.
    • Oncology revenue was $1.68bn (+2.6% YoY). Venclexta growth offset continued declines in Imbruvica.
    • Aesthetics revenue totaled $1.28bn (-8.1% YoY). Botox Cosmetic declined 5%, and Juvederm declined 24%, reflecting market softness and competitive pressures.
    • Eye Care revenue reached $514m (-3.9% YoY). Mixed performance came from Ozurdex and Lumigan within the portfolio.
  • GAAP diluted earnings per share were $0.52 (-32.5% YoY), primarily due to acquired IPR&D and milestone expenses.
  • Adjusted diluted earnings per share were $2.97 (+12.1% YoY), supported by strong product performance and cost discipline.
  • The GAAP operating margin was 31.7%, which reflected ongoing investment in the pipeline and milestone expenses.
  • The adjusted operating margin reached 44.3%, which was supported by top-line growth and SG&A leverage.
  • The adjusted tax rate for the quarter was 16.2%, which remained consistent with management expectations.

AbbVie increased its full-year 2025 adjusted EPS guidance to $11.88-$12.08, which is up from the prior range of $11.67-$11.87. This guidance reflects strong execution across the portfolio and includes an unfavorable $0.55 per share impact from acquired IPR&D and milestone expenses recorded year-to-date. Growth is expected to continue from Skyrizi, Rinvoq, and Neuroscience therapies, while Oncology remains stable and Aesthetics is projected to normalize in the second half of 2025. AbbVie also highlighted ongoing pipeline progress, with recent FDA approvals for Rinvoq in giant cell arteritis and Emrelis for NSCLC, alongside promising late-stage data in alopecia areata and migraine therapies. Management reaffirmed its focus on long-term pipeline expansion, margin discipline, and delivering sustainable shareholder returns.

AbbVie’s stock is currently trading up 3.28% on the last day, showing renewed bullish momentum. The price is positioned slightly above both the 50-day SMA ($188.18) and the 200-day SMA ($187.86), which signals a near-term bullish bias and a potential continuation of the uptrend if support holds. The RSI (14) is at 59.40, indicating that momentum is positive but still below overbought levels, leaving room for further upside. Short-term resistance appears near $200, while the $187-$188 range serves as strong support from the moving averages. A sustained breakout above $200 could open the way to retest previous highs from early 2025.

Source: TradingView

Author: Andreea-Roxana Danci

Similar Posts